iTeos to raise $120M; Xbrane and STA­DA to out-li­cense Lu­cen­tis biosim­i­lar

Plus, news about Anap­tys­Bio, Alza­mend, AEON Bio­phar­ma and ar­genx:

iTeos Ther­a­peu­tics’ $120M of­fer­ing: The im­muno-on­col­o­gy com­pa­ny is sell­ing about 1.1 mil­lion shares for $17.50 apiece. RA Cap­i­tal Man­age­ment and Box­er Cap­i­tal — both ex­ist­ing in­vestors — are lead­ing the fi­nanc­ing. iTeos added that its Phase 2 test of bel­resto­tug plus dostar­limab in metasta­t­ic PD-L1 high non-small cell lung can­cer “ex­ceed­ed pre-de­fined ef­fi­ca­cy cri­te­ria” at an in­ter­im as­sess­ment. Its stock $ITOS was up about 40% on Fri­day morn­ing. — Jaimy Lee & Ay­isha Shar­ma

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER